Home

Roche Holding AG Basel American Depositary Shares (RHHBY)

40.31
-0.29 (-0.71%)
OP · Last Trade: Jul 29th, 4:42 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close40.60
Open40.29
Bid-
Ask-
Day's Range40.09 - 41.55
52 Week Range34.10 - 44.31
Volume955,035
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume1,263,761

Chart

News & Press Releases

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidysbenzinga.com
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Via Benzinga · July 28, 2025
Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey.
By Genentech · Via Business Wire · July 28, 2025
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Loomsstocktwits.com
The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid buildup.
Via Stocktwits · July 27, 2025
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.fool.com
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.
Via The Motley Fool · July 26, 2025
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapybenzinga.com
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Via Benzinga · July 25, 2025
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bouncebackstocktwits.com
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.
Via Stocktwits · July 25, 2025
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Resultsinvestors.com
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via Investor's Business Daily · July 23, 2025
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To USbenzinga.com
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the Phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.
By Genentech · Via Business Wire · July 21, 2025
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Genentech’s supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant.
By Genentech · Via Business Wire · July 18, 2025
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'benzinga.com
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via Benzinga · July 16, 2025
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing'benzinga.com
Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.
Via Benzinga · July 11, 2025
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaroundbenzinga.com
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Via Benzinga · July 7, 2025
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
NetworkNewsWire Editorial Coverage : An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON) , Roche (OTCQX: RHHBY) and…
Via Investor Brand Network · July 7, 2025
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END
Via FinancialNewsMedia · July 7, 2025
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?investors.com
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.investors.com
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.
Via Investor's Business Daily · June 26, 2025
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?investors.com
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Via Investor's Business Daily · June 25, 2025
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upsidebenzinga.com
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.
Via Benzinga · June 23, 2025
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soarsbenzinga.com
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.
Via Benzinga · June 23, 2025
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Druginvestors.com
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
Via Investor's Business Daily · June 23, 2025
Two Biotech Stocks Poised For Big Moves On Mondaybenzinga.com
Via Benzinga · June 23, 2025
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneously in combination with Polivy® (polatuzumab vedotin-piiq) demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR) compared to Rituxan® (rituximab), gemcitabine and oxaliplatin (R-GemOx), in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who are not eligible for transplant. Primary analysis data were featured at the 18th International Conference on Malignant Lymphoma as a late-breaking oral presentation.
By Genentech · Via Business Wire · June 20, 2025
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soarsstocktwits.com
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.
Via Stocktwits · June 18, 2025
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Moodstocktwits.com
The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.
Via Stocktwits · June 16, 2025